Menu
Skip to content
Home
About Us
Services
Products
Contact Us
News & Events
Oncology
Patented products available for R&D use as permitted under 35 USC 271 (e)(1)
A
|
B
|
C
|
D
|
E
|
F
|
G
|
H
|
I
|
J
|
K
|
L
|
M
|
N
|
O
|
P
|
Q
|
R
|
S
|
T
|
U
|
V
|
W
|
X
|
Y
|
Z
A
Abiraterone Acetate
Afatinib
Amifostine
Anastrozole
Ansamitocin P-3
Axitinib
Azacitidine
B
Bleomycin Sulfate
C
Cabazitaxel
Capecitabine
Carboplatin
Cisplatin
Cladribine
Cyclophosphamide
D
Dactinomycin
Dasatinib
Daunorubicin HCl
Decitabine
Degarelix acetate
Docetaxel Anhydrous
Docetaxel Trihydrate
Doxorubicin HCl
E
Epothilone B
Eribulin Mesilate
Erlotinib Base
Erlotinib HCl
Erythromycin Thiocyanate
Etoposide
Everolimus
F
Floxuridine
Fludarabine Phosphate
Fulvestrant
G
Gefitinib
Gemcitabine HCl
I
Ifosfamide
Imatinib Mesylate
Irinotecan HCl
Ixabepilone
L
Lapatinib Ditosylate
Lenalidomide
Letrozole
Lurbinectedin
M
Mercaptopurine
Methotrexate
Mitotane
N
Nilotinib
O
Olaparib
Oxaliplatin
P
Paclitaxel
Palbociclib
Pamidronate Disodium
Panobinostat
Pazopanib HCl
Pegaspargase
Pemetrexed Disodium
Pirarubicin
Pomalidomide
R
Rapamycin (Sirolimus)
Regorafenib
Rivaroxaban
Ruxolitinib Phosphate
S
Sorafenib Tosylate
Sunitinib
T
Talazoparib
Temsirolimus
Triapine
V
Valrubicin
Vinblastine Sulfate
Vincristine Sulfate
Vinorelbine Tartrate
Vorinostat
Z
Zoledronic Acid